utilized PNPLA3‐rs738409‐GG genotype and polygenic risk score to predict cirrhosis risk in patients with NAFLD, achieving AUC values of 0.78 and 0.73, respectively.[31] The combining of the PNPLA3‐rs738409 genotype with diabetes status can identify patients with NAFLD currently considered at uncertain risk of cirrhosis, in a similar way to those currently considered at high risk.[32] Another study used multivariate LR to develop a NASH PT scoring system based on PNPLA3 and TM6SF2 genotypes and clinical factors;[33] the AUC for diagnosing NASH was 0.787–0.859. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatohepatitis.